OpenAI’s updated Model Spec explained through its five core values
QbitAI examines OpenAI’s updated Model Spec, which sets out five core values: faithfulness to human intent, minimizing harm, honesty and transparency, human agency, and care. The explanation highlights contextual use of memory, prohibitions on self-preservation and revenue-seeking goals, and limits on actions beyond user authorization. It also covers stronger protections for users ages 13–17 and OpenAI’s exploration of age-controlled access to erotic and graphic content.
Product releases and updates
Xiaomi open-sources HachimoDock, an AI desktop companion costing about 150 yuan to build
Xiaomi has open-sourced HachimoDock, an AI desktop companion with a reported DIY hardware cost of about 150 yuan. It supports real-time voice interaction with computer-based Agents, customizable pet characters and components, and smart home control through xiaomi Miloco.
Alibaba Cloud launches Qovest AI investment research workspace for professional investors
Alibaba Cloud launched Qovest on November 2 for professional institutional investors, automating data retrieval, analysis, report generation, and scheduled tracking from a natural-language request. Its research workspace retains findings, personal trading notes, and unresolved questions so users can continue earlier work. Individual users can currently request invitation-based access and receive trial credits, with subsequent subscriptions priced at 99 or 199 yuan per month; an enterprise edition is coming soon.
Industry
The Decoder
Saudi Aramco takes 49 percent stake in AI firm Humain with $2.6 billion deal
Saudi Aramco is taking a 49 percent stake in Humain, contributing about $2.6 billion in 2026 along with its own AI technology, according to Aramco. Founded by PIF in May 2025, Humain plans to build three gigawatts of data center capacity by 2030 and serve domestic and international demand. Aramco plans to use the technology in its operations and generate additional revenue by selling its own AI solutions.
Tips and perspectives
莱芒生物 explains its low-dose CAR-T strategy and AI-assisted drug development
莱芒生物 business vice president 仝督读 describes how its META 10-19 CAR-T therapy reached doses as low as 1‰ of conventional levels in early clinical research. He says manual production costs are below 100,000 yuan, with automation projected to bring them below 50,000 yuan. He also describes 晶泰科技’s AI-assisted IL-10 optimization, which delivered initial designs in two weeks, and ongoing AI analysis of clinical samples to investigate relapse.
Tomorrow at 08:00, a briefing like this arrives in your inbox.
The same kind of briefing as the one above: a few stories worth reading. Free. Mail starts after you confirm, and every letter has a one-click unsubscribe. Read a past issue · 2026-11-02